Ironwood Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ironwood Pharmaceuticals, Inc. - overview
Established
1998
Location
Cambridge, MA, US
Primary Industry
Pharmaceuticals
About
Ironwood Pharmaceuticals, Inc. specializes in developing and commercializing innovative gastrointestinal treatments, focusing on improving patient care and health outcomes for those with GI diseases. Founded in 1998 and based in Cambridge, US, Ironwood Pharmaceuticals, Inc. concentrates on gastrointestinal healthcare solutions.
The firm has made a significant pivot towards focusing on the commercialization of treatments for GI disorders. The company successfully went public in 2010, raising USD 188. 00 mn in its IPO and has participated in a total of 9 deals since inception. The CEO, Thomas McCourt, leads the organization, which does not have any noted subsidiaries or parent companies.
Ironwood Pharmaceuticals is a prominent player in the gastrointestinal (GI) healthcare sector, dedicated to developing and marketing novel treatments for GI diseases. Its flagship product, LINZESS (linaclotide), launched in 2012, treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). LINZESS enhances fluid secretion in the intestines, promoting bowel movements. Ironwood's offerings cater to healthcare providers, including gastroenterologists and primary care physicians, as well as patients, ensuring effective management of GI disorders across North America and parts of Europe.
In the most recent year, 2023, Ironwood Pharmaceuticals generated revenue of USD 442. 74 mn. The company's revenue is primarily derived from the sales of prescription medications, particularly LINZESS, through established partnerships with pharmaceutical wholesalers and direct sales to healthcare providers. Despite the revenue generation, Ironwood reported an EBITDA of USD -943.
86 mn in 2023, indicating significant operational costs involved in their business. Ironwood Pharmaceuticals is committed to advancing its product pipeline and expanding its market presence. The company is exploring new treatments for digestive health challenges, with plans to launch additional products in the upcoming years. Ironwood aims to penetrate emerging markets in Europe and Asia by 2025 to broaden access to its GI therapies.
Recent funding from its IPO will be strategically utilized to support research and development initiatives, enhance marketing efforts, and expand distribution networks, ensuring that innovative treatments reach a wider patient base.
Current Investors
Granite Asia, Invus [DUP], SG Growth Capital
Primary Industry
Pharmaceuticals
Sub Industries
Cardiology, Pharmaceutical Research & Development
Website
www.ironwoodpharma.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Ironwood Pharmaceuticals, Inc. - timeline of key events
Ironwood Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.